Stock EOLS EVOLUS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Evolus, Inc.

Equities

EOLS

US30052C1071

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
11.77 USD +0.77% Intraday chart for Evolus, Inc. +7.69% +11.78%
Jul. 01 Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee CI
Jun. 24 Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines' MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Evolus Announces Appointment of Albert G. White III to Board of Directors
BU
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
BU
Evolus Broadens International Presence with Launch of Nuceiva in Spain
AQ
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
BU
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Evolus : Scientific Investor Presentation
PU
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
BU
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau at the Women's Wear Daily Beauty CEO Summit
AQ
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
BU
Evolus Sandra Beaver Named Orange County Business Journal s Public Company CFO of the Year
AQ
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
BU
Evolus Reports First Quarter 2024 Results and Provides Business Update
BU
Evolus to Report First Quarter Financial Results on May 7, 2024
BU
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
BU
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EOLS Stock
  4. News Evolus, Inc.
  5. Press Releases